Compare AEI & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEI | CRVO |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.4M | 89.1M |
| IPO Year | N/A | N/A |
| Metric | AEI | CRVO |
|---|---|---|
| Price | $2.69 | $8.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 37.1K | ★ 79.7K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,108,028.00 | $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $1.80 |
| 52 Week High | $4.55 | $16.94 |
| Indicator | AEI | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 48.39 |
| Support Level | $2.68 | $8.13 |
| Resistance Level | $3.45 | $9.22 |
| Average True Range (ATR) | 0.35 | 0.61 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 26.74 | 23.41 |
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.